CD19 and acute lymphoblastic leukemia: Two recent large-scale CD19-targeted CAR-T clinical trials [9, 11] reported that 20–30% of enrolled patients with B-ALL ultimately were not infused with CAR-T cells due to death from rapid disease progression or CAR-T cell manufacturing failure.